JP2013541706A5 - - Google Patents

Download PDF

Info

Publication number
JP2013541706A5
JP2013541706A5 JP2013528474A JP2013528474A JP2013541706A5 JP 2013541706 A5 JP2013541706 A5 JP 2013541706A5 JP 2013528474 A JP2013528474 A JP 2013528474A JP 2013528474 A JP2013528474 A JP 2013528474A JP 2013541706 A5 JP2013541706 A5 JP 2013541706A5
Authority
JP
Japan
Prior art keywords
biomarker
subject
peptide fragment
apolipoprotein
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013528474A
Other languages
English (en)
Japanese (ja)
Other versions
JP6271250B2 (ja
JP2013541706A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2011/001212 external-priority patent/WO2012037603A1/en
Publication of JP2013541706A publication Critical patent/JP2013541706A/ja
Publication of JP2013541706A5 publication Critical patent/JP2013541706A5/ja
Application granted granted Critical
Publication of JP6271250B2 publication Critical patent/JP6271250B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013528474A 2010-09-21 2011-09-20 糖尿病前症、糖尿病、および糖尿病関連症状に関連するバイオマーカー Active JP6271250B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2010904249A AU2010904249A0 (en) 2010-09-21 Biomarkers associated with pre-diabetes,diabetes and diabetes related conditions
AU2010904249 2010-09-21
PCT/AU2011/001212 WO2012037603A1 (en) 2010-09-21 2011-09-20 Biomarkers associated with pre-diabetes, diabetes and diabetes related conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017136403A Division JP2017223682A (ja) 2010-09-21 2017-07-12 糖尿病前症、糖尿病、および糖尿病関連症状に関連するバイオマーカー

Publications (3)

Publication Number Publication Date
JP2013541706A JP2013541706A (ja) 2013-11-14
JP2013541706A5 true JP2013541706A5 (https=) 2014-11-06
JP6271250B2 JP6271250B2 (ja) 2018-01-31

Family

ID=45873304

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013528474A Active JP6271250B2 (ja) 2010-09-21 2011-09-20 糖尿病前症、糖尿病、および糖尿病関連症状に関連するバイオマーカー
JP2017136403A Pending JP2017223682A (ja) 2010-09-21 2017-07-12 糖尿病前症、糖尿病、および糖尿病関連症状に関連するバイオマーカー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017136403A Pending JP2017223682A (ja) 2010-09-21 2017-07-12 糖尿病前症、糖尿病、および糖尿病関連症状に関連するバイオマーカー

Country Status (11)

Country Link
US (5) US20130177544A1 (https=)
EP (3) EP2619592A4 (https=)
JP (2) JP6271250B2 (https=)
CN (2) CN103299192B (https=)
AU (2) AU2011305050B2 (https=)
BR (1) BR112013006764B1 (https=)
CA (1) CA2811654C (https=)
ES (2) ES2928585T3 (https=)
RU (1) RU2596486C2 (https=)
SG (1) SG188527A1 (https=)
WO (1) WO2012037603A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2928585T3 (es) * 2010-09-21 2022-11-21 Proteomics Int Pty Ltd Biomarcadores asociados con prediabetes, diabetes y condiciones relacionadas con diabetes
US9361429B2 (en) 2012-06-08 2016-06-07 Liposcience, Inc. Multi-parameter diabetes risk evaluations
US9928345B2 (en) 2012-06-08 2018-03-27 Liposciences, Inc. Multiple-marker risk parameters predictive of conversion to diabetes
CN104737020B (zh) * 2012-08-30 2016-08-17 希森美康株式会社 早期肾障碍的评价指标和其测定方法
EP3734609A1 (en) 2013-03-14 2020-11-04 Otraces Inc. A method for improving disease diagnosis using measured analytes
US12546782B2 (en) 2013-03-15 2026-02-10 Mayo Foundation For Medical Education And Research Identification and monitoring of monoclonal immunoglobulins related to monoclonal gammopathy by molecular mass with mass spectrometry
CN103473569A (zh) * 2013-09-22 2013-12-25 江苏美伦影像系统有限公司 基于svm的医学影像分类方法
JP5925391B2 (ja) * 2013-10-16 2016-05-25 日本水産株式会社 ペプチド又はその酸付加塩、飲食品、及び糖尿病予防等の組成物
CA2944767C (en) 2014-04-04 2022-07-12 Mayo Foundation For Medical Education And Research Isotyping immunoglobulins using accurate molecular mass
EP3353200A4 (en) 2015-09-24 2019-06-26 Mayo Foundation for Medical Education and Research IDENTIFICATION OF FREE LIGHT CHAINS FROM IMMOBILIZED LOBULIN BY MASS SPECTROMETRY
RU2021137343A (ru) 2016-01-22 2022-01-26 Отрэйсис, Инк. Системы и способы улучшения диагностики заболеваний
AU2017325022B2 (en) 2016-09-07 2022-10-13 Mayo Foundation For Medical Education And Research Identification and monitoring of cleaved immunoglobulins by molecular mass
WO2018088521A1 (ja) * 2016-11-11 2018-05-17 大塚製薬株式会社 肝の糖取込み能評価方法
EP3358355B1 (en) * 2017-02-04 2023-10-11 Warszawski Uniwersytet Medyczny Use of serum 2-cysteine peroxiredoxins (2-cys-prdx) as biomarkers of chronic kidney diseases (ckd) such as lupus nephritis (ln), iga nephropathy (igan) and autosomal-dominant polycystic kidney disease (adpkd) useful for diagnosing, these diseases and method of differentiation of these diseases
CN106645757B (zh) * 2017-03-13 2019-01-15 新疆医科大学 一种诊断早发糖尿病mody的血清蛋白标志物组及其应用
CN107144620A (zh) * 2017-03-31 2017-09-08 兰州百源基因技术有限公司 糖尿病肾病检测标志物
JP7337701B2 (ja) 2017-03-31 2023-09-04 クエスト ダイアグノスティックス インヴェストメンツ エルエルシー インスリン及びc-ペプチドの定量の方法
CN108732253A (zh) * 2017-04-14 2018-11-02 杭州量康科技有限公司 用于血清蛋白质定量测定的肽段组合物及测定方法
US11946937B2 (en) 2017-09-13 2024-04-02 Mayo Foundation For Medical Education And Research Identification and monitoring of apoptosis inhibitor of macrophage
US12153052B2 (en) 2017-09-13 2024-11-26 Mayo Foundation For Medical Education And Research Identification and monitoring of immunoglobulin J chains
RU2687256C1 (ru) * 2018-03-26 2019-05-08 Федеральное Государственное бюджетное образовательное учреждение высшего образования Дагестанский государственный медицинский университет Министерства здравоохранения Российской Федерации Даггосмедуниверситет Способ персонализированного лечения хронической болезни почек у больных с диабетической нефропатией
TWI822802B (zh) * 2018-06-21 2023-11-21 中國醫藥大學 腎病變蛋白生物標記及其應用
ES3034592T3 (en) * 2018-08-08 2025-08-20 Regeneron Pharma Use of lc-ms/ms to quantitate protein biomarkers
CN110286234B (zh) * 2019-07-02 2023-03-24 安肽和(杭州)医疗科技有限公司 尿液中妊娠糖尿病的蛋白质标志物及其在早期诊断中的用途
CN115023615A (zh) * 2020-01-10 2022-09-06 私募蛋白质体操作有限公司 确定葡萄糖耐量减低的方法
CN111876479A (zh) * 2020-06-29 2020-11-03 中国人民解放军总医院 基于尿沉渣特定微小rna无创鉴别诊断糖尿病肾病/非糖尿病性肾病方面的应用
CN117310148A (zh) * 2023-09-11 2023-12-29 杭州珞米医疗科技有限公司 一种蛋白标志物作为生物标志物的用途
CN118534127A (zh) * 2024-04-12 2024-08-23 郑州大学 补体h因子相关蛋白作为糖尿病肾病诊断的生物标志物的应用
CN121075656B (zh) * 2025-10-31 2026-02-17 中南大学 糖尿病的风险检测方法、装置、计算机设备和介质

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100640201B1 (ko) * 2004-12-07 2006-10-30 (주) 대홍기업 히트파이프가 설치된 도어 조립체 및 이 도어 조립체를채택한 김치저장고
EP1872138A1 (en) * 2005-04-11 2008-01-02 AstraZeneca AB A method and a kit for diagnosing type 2 diabetes, metabolic syndrome, sub clinical atherosclerosis, myocardial infarct, stroke or clinical manifestations of diabetes.
WO2006122043A2 (en) * 2005-05-05 2006-11-16 Fibrogen, Inc. Diagnostic marker for diabetic vascular complications
WO2007028636A1 (en) * 2005-09-09 2007-03-15 Medizinische Universität Innsbruck Method for predicting the progression of chronic kidney disease by measuring apolipoprotein a-iv
CA2625744A1 (en) * 2005-10-11 2007-04-19 Tethys Bioscience, Inc. Diabetes-associated markers and methods of use thereof
US20070111245A1 (en) * 2005-11-09 2007-05-17 Ravi Thadhani Predicting diabetic nephropathy
CN101361001A (zh) * 2006-01-20 2009-02-04 马赛奎斯诊断和治疗有限公司 诊断肾病的方法和标志物
CN101646942A (zh) * 2006-03-23 2010-02-10 埃梅利塔·德古兹曼·布雷耶 载脂蛋白指纹图谱技术
WO2007128884A1 (en) * 2006-05-09 2007-11-15 Oy Jurilab Ltd Novel genes and markers in type 2 diabetes and obesity
KR100792630B1 (ko) * 2006-07-05 2008-01-09 고려대학교 산학협력단 당뇨병성 신증 진단용 바이오 마커
EP2469282A1 (en) * 2006-09-08 2012-06-27 University of Oxford Clinical diagnosis of hepatic fibrosis using a novel panel of human serum protein biomarkers
EP2203743A4 (en) * 2007-09-20 2011-03-02 Univ Louisville Res Found PEPTIDE BIOMARKER FOR PREDICTING WEARNING OF THE KIDNEY FUNCTION AND A CHILDNESS
WO2009103312A1 (en) * 2008-02-19 2009-08-27 Ludwig-Maximilians-Universität Ezrin, serpin b5, peroxiredoxin-2 and heat shock protein beta-1 as autoantigens for psoriasis and poststreptococcal diseases
WO2009126271A1 (en) * 2008-04-11 2009-10-15 China Synthetic Rubber Corporation Methods, agents and kits for the detection of cancer
US8673644B2 (en) * 2008-05-13 2014-03-18 Battelle Memorial Institute Serum markers for type II diabetes mellitus
US20110158979A1 (en) * 2008-06-13 2011-06-30 Prognomix, Inc. Genetic component of complications in type 2 diabetes
WO2010001617A1 (en) * 2008-07-04 2010-01-07 Ono Pharmaceutical Co., Ltd. Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human pd-1 antibody on cancers
US20110311650A1 (en) * 2008-07-07 2011-12-22 Thomas Wang Multiplexed biomarkers of insulin resistance
US8735443B2 (en) * 2008-10-21 2014-05-27 Kuwait University Method of treating diabetes-related vascular complications
EP2391891A1 (en) * 2009-01-27 2011-12-07 Proteogenix, Inc. Biomarkers for detection of neonatal sepsis in biological fluid
US8465980B2 (en) * 2009-01-28 2013-06-18 Industrial Technology Research Institute Urine and serum biomarkers associated with diabetic nephropathy
US9134318B2 (en) * 2009-12-11 2015-09-15 Purdue Research Foundation Detection of oxidized polypeptides
EP2573192A4 (en) * 2010-05-20 2013-11-20 Toru Miyazaki METHOD AND KIT FOR DIAGNOSIS OF AIM-MEDIATED ILLNESSES
ES2928585T3 (es) * 2010-09-21 2022-11-21 Proteomics Int Pty Ltd Biomarcadores asociados con prediabetes, diabetes y condiciones relacionadas con diabetes

Similar Documents

Publication Publication Date Title
JP2013541706A5 (https=)
Kaul et al. Neutrophil gelatinase-associated lipocalin: as a predictor of early diabetic nephropathy in type 2 diabetes mellitus
WO2008060607A3 (en) Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
Bolignano et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease
Scirica Use of biomarkers in predicting the onset, monitoring the progression, and risk stratification for patients with type 2 diabetes mellitus
CA2781754C (en) Diagnostic method for detecting acute kidney injury using heat shock protein 72 as a sensitive biomarker
Lippi et al. Neutrophil gelatinase-associated lipocalin (NGAL): the laboratory perspective.
NZ600828A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2012529015A (ja) 腎臓疾患評価用新規バイオマーカー
WO2010002911A3 (en) Methods and materials for monitoring myeloma using quantitative mass spetrometry
WO2010022210A3 (en) Diagnosis and monitoring of renal failure using peptide biomarkers
NZ619883A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2011510327A5 (https=)
Shaker et al. Serum and urinary transforming growth factor beta 1 as biochemical markers in diabetic nephropathy patients
JP2008241705A (ja) 透析の必要性を予測するためのbnp型ペプチド類の使用
Xiang et al. Clinical application of neutrophil gelatinase-associated lipocalin in the revised chronic kidney disease classification
US20110263438A1 (en) Diagnosis and complication risk assessment of pancreatic diabetes using procalcitonin
Patel et al. Neutrophil gelatinase-associated lipocalin as a biomarker of disease progression in patients with chronic kidney disease
Jung et al. Novel biomarkers for diabetic kidney disease
EA201290627A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
Artunc et al. Comparison of the diagnostic performance of three natriuretic peptides in hemodialysis patients: which is the appropriate biomarker?
Hassan et al. Urinary cystatin C as a biomarker of early renal dysfunction in type 2 diabetic patients
Szczykowska et al. Cardiac troponins in chronic kidney disease patients with special emphasis on their importance in acute coronary syndrome
De Carvalho et al. Assessment of urinary γ-glutamyltransferase and alkaline phosphatase for diagnosis of diabetic nephropathy
Aletras et al. Integrating Novel Biomarkers into Clinical Practice: A Practical Framework for Diagnosis and Management of Cardiorenal Syndrome